
PMC:7784786 / 13157-16527
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
458 | 86-90 | Gene | denotes | IL-6 | Gene:3569 |
459 | 280-284 | Gene | denotes | IL-6 | Gene:3569 |
460 | 367-371 | Gene | denotes | IL-6 | Gene:3569 |
461 | 521-525 | Gene | denotes | IL-6 | Gene:3569 |
462 | 777-781 | Gene | denotes | IL-6 | Gene:3569 |
463 | 913-916 | Gene | denotes | CRS | Gene:7291 |
464 | 213-216 | Gene | denotes | CRS | Gene:7291 |
465 | 11-14 | Gene | denotes | CRS | Gene:7291 |
466 | 178-186 | Species | denotes | patients | Tax:9606 |
467 | 321-329 | Species | denotes | patients | Tax:9606 |
468 | 429-437 | Species | denotes | patients | Tax:9606 |
469 | 602-610 | Species | denotes | patients | Tax:9606 |
470 | 677-685 | Species | denotes | patients | Tax:9606 |
471 | 809-817 | Species | denotes | patients | Tax:9606 |
472 | 881-889 | Species | denotes | patients | Tax:9606 |
473 | 624-634 | Chemical | denotes | itolizumab | MESH:C000597346 |
474 | 169-177 | Disease | denotes | COVID-19 | MESH:C000657245 |
475 | 236-259 | Disease | denotes | hallmark of the disease | MESH:D003141 |
476 | 312-320 | Disease | denotes | COVID-19 | MESH:C000657245 |
477 | 548-556 | Disease | denotes | COVID-19 | MESH:C000657245 |
490 | 1129-1132 | Gene | denotes | CD6 | Gene:923 |
491 | 1194-1197 | Gene | denotes | CD6 | Gene:923 |
492 | 1287-1291 | Gene | denotes | IL-6 | Gene:3569 |
493 | 1293-1298 | Gene | denotes | IFN-γ | Gene:3458 |
494 | 1300-1305 | Gene | denotes | TNF-α | Gene:7124 |
495 | 1310-1315 | Gene | denotes | IL-17 | Gene:3605 |
496 | 1146-1149 | Gene | denotes | CRS | Gene:7291 |
497 | 1170-1178 | Species | denotes | patients | Tax:9606 |
498 | 1031-1039 | Disease | denotes | COVID-19 | MESH:C000657245 |
499 | 1161-1169 | Disease | denotes | COVID-19 | MESH:C000657245 |
500 | 1446-1457 | Disease | denotes | lymphopenia | MESH:D008231 |
501 | 1516-1528 | Disease | denotes | cytotoxicity | MESH:D064420 |
520 | 1788-1791 | Gene | denotes | CD6 | Gene:923 |
521 | 1938-1945 | Gene | denotes | IFNα-2b | Gene:3440 |
522 | 1983-1986 | Gene | denotes | AST | Gene:26503 |
523 | 2178-2181 | Gene | denotes | AST | Gene:26503 |
524 | 1550-1559 | Species | denotes | SARS-CoV2 | Tax:2697049 |
525 | 1560-1568 | Species | denotes | patients | Tax:9606 |
526 | 1660-1668 | Species | denotes | patients | Tax:9606 |
527 | 1726-1733 | Species | denotes | patient | Tax:9606 |
528 | 2135-2143 | Species | denotes | patients | Tax:9606 |
529 | 1746-1752 | Chemical | denotes | oxygen | MESH:D010100 |
530 | 1801-1811 | Chemical | denotes | itolizumab | MESH:C000597346 |
531 | 1901-1920 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
532 | 1922-1933 | Chemical | denotes | chloroquine | MESH:D002738 |
533 | 1586-1606 | Disease | denotes | respiratory distress | MESH:D012128 |
534 | 1621-1654 | Disease | denotes | multifocal interstitial pneumonia | |
535 | 2015-2024 | Disease | denotes | mortality | MESH:D003643 |
536 | 2083-2096 | Disease | denotes | kidney injury | MESH:D058186 |
537 | 2120-2134 | Disease | denotes | critically ill | MESH:D016638 |
543 | 2483-2491 | Species | denotes | patients | Tax:9606 |
544 | 2581-2589 | Species | denotes | patients | Tax:9606 |
545 | 2275-2285 | Chemical | denotes | Itolizumab | MESH:C000597346 |
546 | 2507-2517 | Chemical | denotes | itolizumab | MESH:C000597346 |
547 | 2331-2365 | Disease | denotes | opportunistic secondary infections | MESH:D060085 |
562 | 2629-2633 | Gene | denotes | IL-6 | Gene:3569 |
563 | 2731-2735 | Gene | denotes | IL-6 | Gene:3569 |
564 | 2878-2882 | Gene | denotes | IL-6 | Gene:3569 |
565 | 2982-2986 | Gene | denotes | IL-6 | Gene:3569 |
566 | 2777-2784 | Species | denotes | patient | Tax:9606 |
567 | 3325-3332 | Species | denotes | patient | Tax:9606 |
568 | 2937-2947 | Chemical | denotes | itolizumab | MESH:C000597346 |
569 | 2785-2789 | Disease | denotes | died | MESH:D003643 |
570 | 2823-2851 | Disease | denotes | cardiovascular complications | MESH:D002318 |
571 | 3193-3219 | Disease | denotes | hyperinflammatory syndrome | MESH:D061325 |
572 | 3221-3231 | Disease | denotes | thrombosis | MESH:D013927 |
573 | 3233-3248 | Disease | denotes | alveolar damage | MESH:D055370 |
574 | 3267-3274 | Disease | denotes | hypoxia | MESH:D000860 |
575 | 3333-3337 | Disease | denotes | died | MESH:D003643 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T51 | 1446-1457 | Phenotype | denotes | lymphopenia | http://purl.obolibrary.org/obo/HP_0001888 |
T52 | 1586-1606 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
T53 | 1645-1654 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
T54 | 3267-3274 | Phenotype | denotes | hypoxia | http://purl.obolibrary.org/obo/HP_0012418 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T117 | 0-10 | Sentence | denotes | Discussion |
T118 | 11-73 | Sentence | denotes | CRS is characterized by high levels of inflammatory cytokines. |
T119 | 74-156 | Sentence | denotes | Among them, IL-6 is considered a major mediator of this hyperinflammation [18,19]. |
T120 | 157-265 | Sentence | denotes | Most of the COVID-19 patients-related papers showed the CRS as one of the main hallmark of the disease [20]. |
T121 | 266-335 | Sentence | denotes | Additionally, IL-6 levels predict severity in COVID-19 patients [21]. |
T122 | 336-438 | Sentence | denotes | There is high heterogeneity of IL-6 values among papers for classifying severe and nonsevere patients. |
T123 | 439-586 | Sentence | denotes | In a large meta-analysis of 52 manuscripts, Elshazli and coworkers found that the IL-6 level associated with COVID-19 severity was 22.9 pg/ml [22]. |
T124 | 587-750 | Sentence | denotes | In a series of patients treated with itolizumab a cutoff of 28 pg/ml discriminates severe patients from nonsevere (manuscript just accepted in Immunity and Aging). |
T125 | 751-840 | Sentence | denotes | In the present study, the IL-6 concentration of the three patients was above this cutoff. |
T126 | 841-939 | Sentence | denotes | It confirms the classification of these patients as severe and that the CRS is probably occurring. |
T127 | 940-1051 | Sentence | denotes | Several anticytokine therapies have been tried for treating the hyperinflammatory phase of COVID-19 [20,23–25]. |
T128 | 1052-1179 | Sentence | denotes | Here, we report the use of a well-known anti-inflammatory antibody targeting CD6 to treat the CRS arising in COVID-19 patients. |
T129 | 1180-1411 | Sentence | denotes | Using an anti-CD6 antibody could reduce the concentration of several pro-inflammatory cytokines, including IL-6, IFN-γ, TNF-α and IL-17, among others, representing an advantage as compared with single-cytokine targeting antibodies. |
T130 | 1412-1537 | Sentence | denotes | The antibody would not exacerbate lymphopenia since it does not induce complement or antibody dependent cytotoxicity [10,11]. |
T131 | 1538-1655 | Sentence | denotes | These three SARS-CoV2 patients developed severe respiratory distress together with multifocal interstitial pneumonia. |
T132 | 1656-1760 | Sentence | denotes | Two patients required invasive mechanical ventilation while the third patient only needed oxygen supply. |
T133 | 1761-1946 | Sentence | denotes | They all received the anti-CD6 antibody itolizumab in combination with other drugs incorporated into the Cuban national protocol, including lopinavir/ritonavir, chloroquine and IFNα-2b. |
T134 | 1947-2105 | Sentence | denotes | Regarding to laboratory parameters, AST is strongly associated with mortality risk compared with other parameters, reflecting liver and kidney injury [26,27]. |
T135 | 2106-2274 | Sentence | denotes | In our cases, critically ill patients showed a significant reduction of AST concentration after the treatment suggesting an improvement in the function of these organs. |
T136 | 2275-2366 | Sentence | denotes | Itolizumab was very safe and did not seem to exacerbate opportunistic secondary infections. |
T137 | 2367-2492 | Sentence | denotes | Unfortunately, we did no measure neither the frequency nor the total amount of circulating T cells in these initial patients. |
T138 | 2493-2590 | Sentence | denotes | The impact of itolizumab on circulating T cells are being implementing in new recruited patients. |
T139 | 2591-2772 | Sentence | denotes | Our preliminary findings support that IL-6 levels correlated with the severity of the disease and that the antibody was capable of reducing IL-6 concentration in all three subjects. |
T140 | 2773-2852 | Sentence | denotes | One patient died after subsequent respiratory and cardiovascular complications. |
T141 | 2853-2957 | Sentence | denotes | In this particular case, IL-6 concentration was extremely elevated at the moment of itolizumab infusion. |
T142 | 2958-3075 | Sentence | denotes | Although, the levels of IL-6 decreased during treatment, the values at 7 days kept still very high (above 300 pg/ml). |
T143 | 3076-3156 | Sentence | denotes | There was a transient improvement of respiratory function but it was not enough. |
T144 | 3157-3370 | Sentence | denotes | Presumably, the consequences of the hyperinflammatory syndrome (thrombosis, alveolar damage and severe tissue hypoxia) were irreversible at the moment of treatment and patient died as consequence of these factors. |